Completed PHASE1 INTERVENTIONAL 6-arm NCT00871949

Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults

A Phase 1 Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PNU-100480 (PF-02341272) After First Time Administration Of Ascending Oral Doses To Healthy Adult Subjects Under Fed And Fasted Conditions

Sponsor: Sequella, Inc.

Conditions Tuberculosis

Interventions PNU-100480 Placebo

Updated 6 times since 2017 Last updated: Aug 26, 2013 Started: Apr 30, 2009 Primary completion: Aug 31, 2009 Completion: Aug 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00871949, this PHASE1 trial focuses on Tuberculosis and remains completed. Sponsored by Sequella, Inc., it has been updated 6 times since 2009, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sequella, Inc.

Data source: Sequella, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Haven, United States